198 related articles for article (PubMed ID: 23725711)
1. The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
Abou-Alfa GK; Venook AP
Lancet Oncol; 2013 Jun; 14(7):e283-8. PubMed ID: 23725711
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials of antiangiogenic therapy for hepatocellular carcinoma.
Taketomi A
Int J Clin Oncol; 2016 Apr; 21(2):213-218. PubMed ID: 26899258
[TBL] [Abstract][Full Text] [Related]
3. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).
Pazo-Cid RA; Lanzuela M; Esquerdo G; Pérez-Gracia JL; Antón A; Amigo G; Trufero JM; García-Otín AL; Martín-Duque P
Clin Transl Oncol; 2012 Aug; 14(8):564-74. PubMed ID: 22855137
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Weintraub JL; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic strategies in hepatocellular carcinoma: current status.
Zacharoulis D; Hatzitheofilou C; Athanasiou E; Zacharoulis S
Expert Rev Anticancer Ther; 2005 Aug; 5(4):645-56. PubMed ID: 16111465
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy.
Lu LC; Shao YY; Chan SY; Hsu CH; Cheng AL
Anticancer Res; 2014 Feb; 34(2):1047-52. PubMed ID: 24511053
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy of hepatocellular carcinoma: present and future.
Chan SL; Yeo W
J Gastroenterol Hepatol; 2012 May; 27(5):862-72. PubMed ID: 22369685
[TBL] [Abstract][Full Text] [Related]
8. Molecular targeted therapies in hepatocellular carcinoma.
Tanaka S; Arii S
Semin Oncol; 2012 Aug; 39(4):486-92. PubMed ID: 22846865
[TBL] [Abstract][Full Text] [Related]
9. Molecularly targeted therapy in hepatocellular carcinoma.
Huynh H
Biochem Pharmacol; 2010 Sep; 80(5):550-60. PubMed ID: 20371362
[TBL] [Abstract][Full Text] [Related]
10. An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.
Raoul JL; Gilabert M; Adhoute X; Edeline J
Expert Opin Pharmacother; 2017 Oct; 18(14):1467-1476. PubMed ID: 28893090
[TBL] [Abstract][Full Text] [Related]
11. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C
Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Liu LP; Ho RL; Chen GG; Lai PB
Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
[TBL] [Abstract][Full Text] [Related]
13. Emerging targeted strategies in advanced hepatocellular carcinoma.
Finn RS
Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
15. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
[TBL] [Abstract][Full Text] [Related]
16. AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
Gamstätter T; Weinmann A; Schadmand-Fischer S; Spies PR; Niederle IM; Schuchmann M; Galle PR; Wörns MA
Onkologie; 2011; 34(10):538-42. PubMed ID: 21985853
[TBL] [Abstract][Full Text] [Related]
17. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Yau T; Pang R; Chan P; Poon RT
Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment of hepatocellular carcinoma.
Germano D; Tinessa V; Barletta E; Cannella L; Daniele B
Minerva Med; 2013 Oct; 104(5):545-61. PubMed ID: 24101112
[TBL] [Abstract][Full Text] [Related]
19. New strategy of antiangiogenic therapy for hepatocellular carcinoma.
Wu XZ
Neoplasma; 2008; 55(6):472-81. PubMed ID: 18999874
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
Sieghart W; Pinter M; Dauser B; Rohr-Udilova N; Piguet AC; Prager G; Hayden H; Dienes HP; Dufour JF; Peck-Radosavljevic M
J Hepatol; 2012 Sep; 57(3):592-9. PubMed ID: 22634341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
